Cartesian Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Cartesian Therapeutics, Inc. (RNAC) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $49.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-09
- Cartesian Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $49.00M, a 60.36% decline from fiscal 2024.
- Cartesian Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $123.60M.
- Cartesian Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$3.50M.
- Cartesian Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$3.50M, a 115.63% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $49.00M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $123.60M 10-K · filed 2026-03-09 | |
| 2023-12-31 | -$3.50M 10-K · filed 2024-03-07 | |
| 2022-12-31 | -$3.50M 10-K · filed 2025-03-13 | -$1.50M 10-K · filed 2023-03-02 |
| 2021-12-31 | $22.40M 10-K · filed 2023-03-02 | |
| 2020-12-31 | $16.30M 10-K · filed 2022-03-10 | |
| 2019-12-31 | $14.60M 10-K · filed 2021-03-12 | |
| 2018-12-31 | $14.60M 10-K · filed 2020-03-12 | $18.50M 10-K · filed 2019-03-15 |
| 2017-12-31 | $18.50M 10-K · filed 2020-03-12 | $4.70M 10-K · filed 2018-03-15 |
| 2016-12-31 | $14.40M 10-K · filed 2018-03-15 | |
| 2015-12-31 | $10.10M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |